Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy.